JP2024515165A - 抗ｋｌｒｇ１抗体 - Google Patents

抗ｋｌｒｇ１抗体 Download PDF

Info

Publication number
JP2024515165A
JP2024515165A JP2023558946A JP2023558946A JP2024515165A JP 2024515165 A JP2024515165 A JP 2024515165A JP 2023558946 A JP2023558946 A JP 2023558946A JP 2023558946 A JP2023558946 A JP 2023558946A JP 2024515165 A JP2024515165 A JP 2024515165A
Authority
JP
Japan
Prior art keywords
seq
antibody
antigen
cancer
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023558946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515165A5 (https=
Inventor
ヴイ． ガラ ステファノ
エヴァン トンプソン ケネス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Abcuro Inc
Original Assignee
Abcuro Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abcuro Inc filed Critical Abcuro Inc
Publication of JP2024515165A publication Critical patent/JP2024515165A/ja
Publication of JP2024515165A5 publication Critical patent/JP2024515165A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023558946A 2021-03-26 2022-03-25 抗ｋｌｒｇ１抗体 Pending JP2024515165A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163166663P 2021-03-26 2021-03-26
US63/166,663 2021-03-26
US202163294436P 2021-12-29 2021-12-29
US63/294,436 2021-12-29
PCT/US2022/021945 WO2022204514A1 (en) 2021-03-26 2022-03-25 Anti-klrg1 antibodies

Publications (2)

Publication Number Publication Date
JP2024515165A true JP2024515165A (ja) 2024-04-05
JP2024515165A5 JP2024515165A5 (https=) 2025-04-15

Family

ID=81385062

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023558946A Pending JP2024515165A (ja) 2021-03-26 2022-03-25 抗ｋｌｒｇ１抗体

Country Status (10)

Country Link
US (1) US20240174754A1 (https=)
EP (1) EP4314066A1 (https=)
JP (1) JP2024515165A (https=)
KR (1) KR20230162798A (https=)
AU (1) AU2022246164A1 (https=)
BR (1) BR112023019512A2 (https=)
CA (1) CA3212311A1 (https=)
IL (1) IL307241A (https=)
MX (1) MX2023011102A (https=)
WO (1) WO2022204514A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112021004553A2 (pt) 2018-09-17 2021-06-08 Abcuro, Inc. anticorpos anti-klrg1

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169229A1 (en) * 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
WO2020060781A1 (en) * 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
WO2020210512A1 (en) * 2019-04-09 2020-10-15 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
JP2019518791A (ja) * 2016-06-03 2019-07-04 ザ・ブリガム・アンド・ウィメンズ・ホスピタルＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ Ｋｌｒｇ１シグナリングセラピー

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019169229A1 (en) * 2018-03-01 2019-09-06 Nextcure, Inc. Klrg1 binding compositions and methods of use thereof
WO2020060781A1 (en) * 2018-09-17 2020-03-26 Abcuro, Inc. Anti-klrg1 antibodies
WO2020210512A1 (en) * 2019-04-09 2020-10-15 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies

Also Published As

Publication number Publication date
WO2022204514A1 (en) 2022-09-29
AU2022246164A9 (en) 2024-02-22
CA3212311A1 (en) 2022-09-29
BR112023019512A2 (pt) 2023-10-31
AU2022246164A1 (en) 2023-09-28
KR20230162798A (ko) 2023-11-28
MX2023011102A (es) 2023-11-28
IL307241A (en) 2023-11-01
US20240174754A1 (en) 2024-05-30
EP4314066A1 (en) 2024-02-07

Similar Documents

Publication Publication Date Title
US10947314B2 (en) Antibodies targeting b-cell maturation antigen and methods of use
US9447182B2 (en) Antibodies directed against the alpha chain of IL7 receptor—their use for the preparation of drug candidates
US12139541B2 (en) Methods of treating disorders associated with excess or unwanted killer cell lectin-like receptor subfamily g member 1 (KLRG1) expressing t cells with KLRG1 depleting antibodies
IL285101B1 (en) G protein-coupled receptor-directed antibodies and methods of use
US11497769B2 (en) Anti-CD19 antibodies
JP6254522B2 (ja) ヒト化抗ｃｄ５２抗体
AU2018278051A1 (en) Anti-CD40 antibody, antigen binding fragment thereof and medical use thereof
JP7796008B2 (ja) 抗ｃｄ３７１抗体およびその使用
WO2024175030A1 (zh) 抗Nectin-4抗体和包含其的多特异性抗体
US20240174754A1 (en) Anti-klrg1 antibodies
JP2024528877A (ja) キラー細胞レクチン様受容体サブファミリーｇメンバー１（ｋｌｒｇ１）枯渇性抗体
WO2022212836A1 (en) Gpnmb antibodies and methods of use
CA3254085A1 (en) KLRB1 LIAISON AGENTS AND THEIR METHODS OF USE
WO2022204529A1 (en) Anti-klrg1 antibodies
CN117321082A (zh) 抗klrg1抗体
TW202323293A (zh) 新型抗ｉｌ－３６ｒ抗體

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240105

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240314

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20241024

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250124

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250317

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250325

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251209

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20260212